Ad Break 1

Ad Break 2

Outro

Jockeying over patents is driving investment and competition among the growing number of people and companies trying to profit from the psychedelics renaissance. Graham Pechenik is one of the smartest and most respected attorneys specializing in this area. We started off by discussing a recent victory against the DEA, which had tried to put a number of promising compounds into Schedule I. Most of our conversation thereafter focused on current battles among investors, activists and researchers, the challenges of trying to reform a patent system that is widely seen as flawed and even broken, and alternative paths for maximizing the benefits and accessibility of psychedelic medicine.

<p>Jockeying over patents is driving investment and competition among the growing number of people and companies trying to profit from the psychedelics renaissance. Graham Pechenik is one of the smartest and most respected attorneys specializing in this area. We started off by discussing a recent victory against the DEA, which had tried to put a number of promising compounds into Schedule I. Most of our conversation thereafter focused on current battles among investors, activists and researchers, the challenges of trying to reform a patent system that is widely seen as flawed and even broken, and alternative paths for maximizing the benefits and accessibility of psychedelic medicine.</p>

Drugs, drugs, drugs. Almost everyone uses them. Almost everyone has an opinion about them. Drug policy pioneer Ethan Nadelmann gets to the bottom of our strange relationship to drugs by talking with those who love them, hate them, and study them.
We’d love to hear your stories and ideas. Send us a note at psychoactive@protozoa.com or leave a voicemail at 1-833-PSYCHO-0 (1-833-779-2460).

PSYCHOACTIVE

Graham Pechenik on Psychedelic Patents & Law

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/89104502-736e-4c46-8fa5-af180021f820/transcript

Advertisement